Key Points {#d30e280}
==========

C~60~ fullerene protects the heart and liver of tumor-bearing animals against doxorubicin (Dox)-induced oxidative stress.Combined antitumor treatment of C~60~ fullerene and Dox is more effective than Dox treatment alone.

Introduction {#Sec1}
============

Oncological diseases, particularly lung cancer, breast cancer, and leucosis, are common and carry a high mortality rate. Several cytostatic drugs, including doxorubicin (Dox), are used in the therapy of malignant tumors. Dox is an antibiotic of the anthracycline group, with a wide range of clinical activity against solid tumors and hemoblastoses, lung carcinoma, and acute leukemia \[[@CR1]\]. Dox non-covalently binds to DNA, blocking the synthesis of nucleic acids, and demonstrates high antimitotic activity and pronounced mutagenic effect, but exerts toxic effects in normal tissues and cells \[[@CR2]\].

One approach to protect against Dox-induced chemical insult to normal tissues is a combined use of the cytostatic drug with antioxidants of a different nature \[[@CR3]\]. C~60~ fullerene has recently been recognized as a promising agent for use in anticancer therapy \[[@CR4], [@CR5]\]. C~60~ fullerene and its derivatives are biocompatible, show no toxic effects on normal tissues at low concentrations, possess strong free-radical-scavenging and antioxidant potential \[[@CR6]--[@CR10]\], and demonstrate a protective effect against Dox-induced chronic cardio- and hepatotoxicity \[[@CR11]\]. The tumor-inhibitory activity of nanoparticles containing C~60~ fullerene has been studied in models of murine hepatocarcinoma \[[@CR12]\] and rat colorectal cancer and mammary carcinoma \[[@CR3], [@CR13], [@CR14]\]. Finally, recent results indicate that C~60~ fullerene complexation with Dox may be a key process leading to alteration of the antitumor effect of Dox in vitro \[[@CR15], [@CR16]\].

The study of the biological effects of pristine C~60~ fullerene is limited by its hydrophobicity, difficulties involved with reaching sufficient concentration, and aggregation in water \[[@CR17]\]. For this reason, hydrophilic derivatives obtained by chemical modification of the C~60~ fullerene outer surface were used in most studies of C~60~ fullerene antioxidant and antineoplastic effects \[[@CR10], [@CR12], [@CR18]\]. However, derivatization does not completely prevent cluster formation. Moreover, substantial modification of the C~60~ fullerene core appears to cause a perturbation of the *π*-conjugated electronic system of cyclohexatriene units on the molecular surface and hence may influence C~60~ fullerene reactivity \[[@CR19], [@CR20]\]. The use of a stable water colloid dispersion of pristine C~60~ fullerene has shown promise for the comprehensive analysis of C~60~ fullerene biological effects and antitumor efficiency \[[@CR21]\].

The aim of this study was to estimate the antitumor effect and antioxidant enzyme activity in the liver and heart of mice with Lewis lung carcinoma (LLC) after combined treatment with C~60~ fullerene and Dox as compared with treatment with Dox alone.

Materials and Methods {#Sec2}
=====================

Chemicals {#Sec3}
---------

Dox (Ebewe, Austria), paraformaldehyde, paraplast (Richard-Allan Scientific, USA), DC Protein (Bio-Rad, USA), superoxide dismutase (SOD), and glutathione peroxidase (GP) assay kits were purchased from Fluka (Buchs, Switzerland) and Sigma-Aldrich (Saint Louis, USA).

Preparation of Pristine C~60~ Fullerene Water Colloid Solution {#Sec4}
--------------------------------------------------------------

The C~60~ fullerene powder with a purity of \>99.8 % was prepared according to a published protocol \[[@CR22]\]. The highly stable and reproducible pristine C~60~ fullerene aqueous colloid solution (C~60~FAS; concentration 1.0 mg/ml, purity \>99.5 %) was prepared, as published previously \[[@CR23]\], by the transfer of C~60~ fullerene molecules from toluene to an aqueous phase with the help of ultrasonic treatment.

Atomic Force Microscopy Characterization of C~60~ Fullerene Aqueous Colloid Solution {#Sec5}
------------------------------------------------------------------------------------

The state of C~60~ fullerene in aqueous solution was monitored using atomic force microscopy (AFM; 'Solver Pro M' system; NT-MDT, Russia). The samples were deposited by precipitation from an aqueous solution droplet onto cleaved mica substrate (V-1 Grade, SPI Supplies). Measurements were performed after complete evaporation of the solvent. The sample visualization was carried out in semicontact (tapping) mode with NSG10 (NT-MDT) probes.

Animals {#Sec6}
-------

Male C57Bl/6J mice (20--22 g) were kept at 20 ± 1 °C with free access to standard laboratory diet and water. All experiments were performed according to the international principles of the European Convention on protection of vertebrate animals used for experimental purposes.

Treatment Protocol {#Sec7}
------------------

LLC cells (\~5 × 10^5^) were subcutaneously inoculated into the limb of each mouse. The treatment was started on the 7th day after tumor inoculation when the tumor had grown up to approximately 5 mm. Tumor-bearing mice were randomly divided into four groups, with 12 animals per group.

Mice in the Dox group and the C~60~ fullerene group received intraperitoneal (ip) injection of 0.5 mg/kg of Dox and 5 mg/kg of C~60~ fullerene, respectively, as a daily dose for 5 consecutive days with a 1-day interval \[[@CR4]\]. Mice in the C~60~ + Dox group received C~60~FAS ip (dose 5 mg/kg) 20 min before the Dox injection (dose 0.5 mg/kg). The control cancer group received saline ip only. On the 22nd day after tumor inoculation (when the first tumor-bearing animal died in the control cancer group), each group was randomly divided into two groups; six mice from each group were sacrificed and tissues were taken for analysis. The remaining six mice in each group were used to estimate the lifespan.

Assay of Antitumor Effects {#Sec8}
--------------------------

The antitumor efficiency of the applied technique was estimated with the following quantitative indexes:tumor volume: $\documentclass[12pt]{minimal}
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Histological Studies {#Sec9}
--------------------

For histological analysis, tumor tissue was dissected, fixed in 4 % paraformaldehyde, pH 7.4, dehydrated in ethanol, embedded at paraplast, and cut into 4 μm slices. After staining with hematoxylin-eosin (HE), cyto-morphological characteristics of tumor sections were studied using light microscopy (Olympus BX51, Japan). The average number of mitotic (with the specific pattern of chromatin condensation) and apoptotic (with fragmented nucleus and apoptotic bodies) cells was estimated in sections with the use of 'Olympus DP-Soft' morphometric software.
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Measurement of Antioxidant Enzyme Activity {#Sec10}
------------------------------------------

The liver and heart were quickly removed from the scarified mice, placed into an ice-cold solution, minced, and homogenized in 10 mM Tris--HCl, pH 8.0. The samples were centrifuged at 13,000*g* for 20 min at 4 °C. Supernatants were used for the assay of total protein concentration and spectrophotometric analysis of enzyme activity. Protein concentration was determined using a DC Protein Assay Kit.

SOD activity was measured using a competition assay between SOD and indicator molecule, nitroblue tetrazolium (NBT). One unit of activity was defined as the concentration of SOD that had inhibited the NBT reduction rate to half of the maximum. GP activity was estimated in potassium buffer containing reduced glutathione, NaN~3~, to inhibit catalase and H~2~O~2~ as the substrate by monitoring accumulation of glutathione disulfide (GSSG).

Statistics {#Sec11}
----------

Statistical analysis of experimental data was performed using the Statistica-6.0 computer program (StatSoft Inc.). Validity of differences between the control and experimental measurements was estimated via the Student's *t-*test (values are given as mean ± standard error; the differences between the compared values were considered meaningful at *p* \< 0.05).

Results and Discussion {#Sec12}
======================

Structure of C~60~ Fullerene Nanoparticles in Aqueous Colloid Solution {#Sec13}
----------------------------------------------------------------------

Knowledge of the C~60~ fullerene aggregation parameters in aqueous solution is important for estimation of nanostructure bioactivity and its potential for biomedical application \[[@CR18], [@CR24], [@CR25]\]. An AFM investigation was performed to characterize the aggregation state of C~60~ fullerene in aqueous solution.

The AFM image (Fig. [1](#Fig1){ref-type="fig"}) demonstrates that, along with the individual C~60~ fullerenes, their bulk aggregates (clusters) with a diameter of up to 50 nm were present on the mica substrate. These results are in a good agreement with the data from laser correlation spectroscopy of C~60~FAS, which confirm that the average hydrodynamic diameter of nanoparticles is 50 nm and no further agglomeration is observed \[[@CR26]\]. More detailed analysis of the structural composition and physico-chemical properties of C~60~FAS has been previously accomplished \[[@CR21], [@CR23]\] by means of chemical analysis, ultraviolet-visible spectroscopy (UV/VIS) and Fourier transform infrared spectroscopy (FTIR), scanning tunneling microscopy, dynamic light scattering, and small-angle neutron scattering techniques. In general, the properties of the C~60~FAS used in this experiment correspond to those in the published literature data.Fig. 1Atomic force microscopy image of C~60~ fullerene nanoparticles precipitated on mica surface from C~60~FAS (0.1 mg/ml)

Tumor Growth-Inhibitory Effects {#Sec14}
-------------------------------

In traditional animal tumor models, Dox is typically introduced at concentrations of up to 100 mg/kg; however, high lethality complicates prolonged monitoring of Dox effects. Injection of the chemotherapeutic agent in lower doses is more effective than a single injection at an equivalent dose \[[@CR2]\].

In our experiments, we used a model of multiple ip injections for a course of Dox treatment with a total dose of 2.5 mg/kg (corresponding to a minimal therapeutic dose), and in combination with C~60~ fullerene as a potential antitumor agent and protector against Dox-induced toxicity. The total dose of C~60~ fullerene (25 mg/kg) was non-toxic as expected, since the median lethal dose (LD~50~) for pristine C~60~ fullerene ip injected in a water solution to mice was found to be approximately 600 mg/kg \[[@CR6]\].

The kinetics of average tumor volume extension that manifests the tumor growth was measured in three experimental groups of animals from the 7th to 22nd day after tumor inoculation and compared with that of the control cancer group. The tumor growth inhibition curves for the various groups are shown in Fig. [2](#Fig2){ref-type="fig"}. The tumors grew the quickest in the control group. Tumor inhibitory effect in the C~60~ fullerene-treated group (22.5 %) was comparable with that in the Dox-treated group (24.2 %). When C~60~ fullerene was administered before Dox (C~60~ + Dox group), a stronger inhibitory effect was observed (36.2 %). Thus, these data indicate that treatment with C~60~ + Dox more effectively inhibits tumor growth than does treatment with Dox or C~60~ fullerene separately.Fig. 2Growth inhibition curves for treatment of tumor-bearing animals with C~60~ fullerene, doxorubicin, or C~60~ + doxorubicin (*p* \< 0.05)

Quantitative Indexes of Antitumor Effect {#Sec15}
----------------------------------------

Data on the lifespan of the control and treated groups are presented in Table [1](#Tab1){ref-type="table"}. The last animal in the control cancer group died on the 30th day of the experiment, whereas the lifespan of animals in experimental groups was found to be increased. The last animal in the Dox group died on the 38th day, and those in the C~60~ fullerene and C~60~ + Dox groups died on the 40th day.Table 1Lifespan of animals in different groupsDays after tumor inoculationTreatment group (*n*)Cancer controlDoxorubicinC~60~ fullereneC~60~ + doxorubicin22666624255526124283300332234136138014000

Table [2](#Tab2){ref-type="table"} shows the quantitative indexes of animal life prolongation (*k*~p~) and metastasis inhibition (*k*~m~) as the measure of the total effectiveness of the applied regimes of antitumor treatment.Table 2Indexes of metastasis inhibition (*k* ~m~) and animal life prolongation (*k* ~p~) in groups of treated tumor-bearing miceTreatment*k* ~m~, %*k* ~p~, %Doxorubicin23 ± 4\*16 ± 4C~60~ fullerene15 ± 224 ± 4\*C~60~ + doxorubicin35 ± 5\*32 ± 5\*\* *p* \< 0.05 compared with the cancer control group (untreated animals)

LLC cells are highly invasive and quickly spread into lung tissue and form multiple metastases. Dox treatment distinctly inhibited tumor dissemination into the lung of tumor-bearing animals (*k*~m~ \~ 23 %) but exerted only a slight effect on life prolongation (*k*~p~ *\~* 16 %). In the C~60~ fullerene-treated group, the metastasis inhibition index was less than that in the Dox-treated group (*k*~m~ \~ 15 %), but the life prolongation was greater (*k*~p~ *\~* 24 %). Both the anti-metastatic effect (*k*~m~ \~ 35 %) and the life prolongation (*k*~p~ *\~* 32 %) were found to be maximal in the C~60~ + Dox group.

Cytomorphological Changes in Tumor Tissue {#Sec16}
-----------------------------------------

Cytomorphological study of the tumor that developed subcutaneously in mice in the cancer control group (Fig. [3](#Fig3){ref-type="fig"}a) showed that it consisted of polymorphic cells with a nucleus, large nucleolus, condensed chromatin, and light areas of tumor karyoplasm. The high content of mitotic cells testifies to the proliferative potential of tumor cells. In the C~60~ fullerene-treated group, the tumor mitotic index did not change, but the apoptotic index was found to be higher than in the control cancer group (Figs. [3](#Fig3){ref-type="fig"}b and [4](#Fig4){ref-type="fig"}). Dox treatment was followed by a reduction in the number of mitotic cells and an increase in the number of apoptotic cells, i.e. by inhibition of proliferative potential and induction of tumor cell death (Figs. [3](#Fig3){ref-type="fig"}c, [4](#Fig4){ref-type="fig"}). When the tumor-bearing animals were exposed to treatment with C~60~ + Dox, the number of apoptotic cells substantially increased and zones containing apoptotic, necrotic cells and infiltrating macrophages were detected (Figs. [3](#Fig3){ref-type="fig"}d and [4](#Fig4){ref-type="fig"}).Fig. 3Histological sections of hematoxylin--eosin-stained tumor tissue (magnification × 400): (**a**) cancer control group, (**b**) C~60~ fullerene group, (**c**) doxorubicin group, (**d**) C~60~ + doxorubicin group. *A* apoptosis, *M* mitosis, *N* necrosis, *\**indicates macrophageFig. 4Tumor mitotic and apoptotic indexes in groups of treated tumor-bearing mice. \**p* \< 0.05 vs. the cancer control group (untreated animals). *C* ~*60*~ C~60~ fullerene, *Dox* doxorubicin

Activity of Antioxidant Enzymes in Liver and Heart {#Sec17}
--------------------------------------------------

Dox chemotherapy is known to be accompanied by the generation of reactive oxygen species (ROS) and immediate oxidative damage of cells with high oxidative metabolism and activity of mitochondrial respiratory chain, particularly cardiac myocytes and hepatocytes. SOD and GP are the predominant antioxidant enzymes. The first step of antioxidant defense is the dismutation of superoxide anion into hydrogen peroxide by inducible SOD; the second is conversion of hydrogen peroxide to water by GP. The activity of SOD and GP was estimated in the liver and heart of animals in the cancer control, Dox-, and C~60~ + Dox-treated groups. No reliable difference in the level of heart and liver antioxidant enzymes in the C~60~ fullerene group as compared with the cancer control group was observed.

Prolonged Dox administration resulted in a decrease of SOD as well as of GP activities in both mice liver and mice heart (Fig. [5](#Fig5){ref-type="fig"}). Since activity of both enzymes is known to undergo feedback inhibition by excessive levels of peroxides and lipoperoxides, it could be that Dox-dependent oxidative stress diminishes ROS-scavenging activity of SOD and GP in the liver and heart of tumor-bearing animals.Fig. 5Activity of superoxide dismutase and glutathione peroxidase in the livers and hearts of treated tumor-bearing mice. \**p* \< 0.05 vs. the cancer control group (untreated animals), \*\**p* \< 0.05 vs. the doxorubicin group. *C* ~*60*~ C~60~ fullerene, *Dox* doxorubicin, *GP* glutathione peroxidase, *SOD* superoxide dismutase

No inhibition of antioxidant enzyme activity was detected in the C~60~ + Dox-treated group; the level became comparable with that in the control group (SOD activity in liver and heart and GP activity in heart) or even exceeded that in the control group (GP in liver) (Fig. [5](#Fig5){ref-type="fig"}). This favorable phenomenon is likely to be associated with the ability of C~60~ fullerene to function as a ROS scavenger or SOD mimetic \[[@CR27]\] and to decrease the production of ROS to the optimal level for antioxidant enzyme activation. Up-regulation of SOD has previously been shown to enhance cell survival in the presence of Dox through its role as a free radical scavenger \[[@CR28]\]. In addition, overexpression of cytosolic and mitochondrial GP appeared to protect mice hearts against Dox-induced cardiotoxicity and to prevent impairment of mitochondrial respiration and inhibition of complex I activity \[[@CR29]\].

This study has shown that the treatment of tumor-bearing mice with ip injection of C~60~ + Dox from the 7th day after LLC cell inoculation resulted in tumor growth slowdown, metastasis inhibition, and lifespan prolongation. These indexes were also increased after Dox or C~60~ fullerene were administered as single agents, but the antitumor effect was most pronounced in the C~60~ + Dox group. The histological analysis of tumor tissue in the C~60~ + Dox-treated group confirmed the inhibition of proliferating tumor cells, induction of apoptotic and necrotic cell death, and macrophage infiltration.

In several previous in vitro studies, internalization of pristine C~60~ fullerene into cancer cells was demonstrated, but no cytotoxic effects were observed. When human lung carcinoma A549 cells were exposed to pristine C~60~ fullerene dispersion (particle size 100--200 nm), internalized C~60~ fullerene aggregates were detected in the cytoplasm and lysosomes. Neither apoptosis nor necrosis was induced, while cell proliferation was inhibited \[[@CR30]\]. Malignant breast epithelial cells were shown to take up pristine C~60~ fullerene from methanol C~60~ fullerene solution (particle size 106--342 nm), and the treatment of these cells with C~60~ fullerene up to 200 μg/ml did not alter the morphology, cytoskeleton organization, cell cycle dynamics, or cell proliferation \[[@CR31]\].

Other studies on pristine C~60~ fullerene distribution in animal tissues after ip administration demonstrated nanoparticle uptake into the circulation, accumulation in the liver at 120 min post-exposure, and nearly complete elimination by day 13, with minimal accumulation in the spleen, lung, and muscle \[[@CR6], [@CR32]\].

Internalization of C~60~ fullerene in tumor tissue has also been demonstrated with in vivo models and different water-soluble C~60~ fullerene derivatives. In a mouse model of liver cancer, malonodiserinolamide-derivatized C~60~ fullerene nanoparticles were detected permeating through the altered vasculature of the tumor, evading the reticulo-endothelial system \[[@CR33]\]. Gd\@C~82~(OH)~22~ nanoparticles administered ip at a dose level of approximately 10^−7 ^mol/kg were shown to exhibit high antineoplastic activity against murine H22 hepatocarcinoma, but only 0.05 % of the exposed dose reached the tumor tissue \[[@CR34]\]. It was also demonstrated that fullerol C~60~(OH)~x~ nanoparticles were mainly taken up by the mononuclear phagocyte system, and only 0.2 % were accumulated in the murine H22 hepatocarcinoma within 24 h due to enhanced permeability and retention effects \[[@CR35]\]. Nevertheless, C~60~(OH)~x~ in doses of 0.2 and 1 mg/kg was found to exhibit significant tumor-inhibitory activity \[[@CR12]\].

Considering that no marked accumulation of C~60~ fullerene was detected in tumors and no direct toxic effect on tumor cells was observed, it is assumed that antitumor efficiency of C~60~ fullerene derivatives is not due to the direct killing of tumor cells but is the result of tumor microenvironment regulation and/or immune response activation \[[@CR12], [@CR36]--[@CR38]\]. On the other hand, our finding of C~60~ fullerene-dependent enhancement of Dox antitumor effect does not exclude the possibility that C~60~ fullerene nanoparticles promote Dox accumulation in tumor cells by activating drug endocytosis, as it was shown for Gd\@C~82~(OH)~22~ nanoparticles that may restore defective endocytosis of cisplatin by cancer cells \[[@CR39]\].

The most severe side effect of Dox treatment is free radical-mediated damage to liver and heart tissue, which are very sensitive to free radical damage because of their high oxidative metabolism. In this study, we have demonstrated a beneficial effect of pristine C~60~ fullerene in a low-dose regime (5 mg/kg) on heart and liver antioxidant defense against Dox treatment in tumor-bearing mice. The greater protective effect of lower doses of fullerols (25 mg/kg) in contrast to higher doses (50 and 100 mg/kg) against Dox-associated toxicity was confirmed for rat hearts and livers with colorectal cancer \[[@CR3], [@CR40]\]. This observation is likely to be associated with the fact that the higher doses were less well absorbed from the peritoneal cavity.

In summary, we can conclude that pristine C~60~ fullerene exhibits health effects and antitumor activity in combined treatment with Dox. These results need to be investigated further in a number of tumor models.
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